Modality
siRNA
MOA
GLP-1/GIP
Target
Tau
Pathway
mTOR
SCD
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
~Jul 2018
→ ~Oct 2019
Phase 2
~Jan 2020
→ ~Apr 2021
Phase 3
~Jul 2021
→ ~Oct 2022
NDA/BLA
Jan 2023
→ Dec 2025
NDA/BLACurrent
NCT03725231
2,033 pts·SCD
2023-01→2025-12·Recruiting
2,033 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-12-203mo agoPh3 Readout· SCD
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2025-12-20 · 3mo ago
SCD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03725231 | NDA/BLA | SCD | Recruiting | 2033 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| BEA-4274 | Beam | Phase 1/2 | ALK | |
| PST-2276 | Poseida | Approved | Aβ | |
| TER-5062 | Terns | Phase 2/3 | Tau |